Lakewood-Amedex faces Nasdaq delisting over minimum bid price violation
LABT•Nasdaq notified Lakewood-Amedex Biotherapeutics on November 10 that its stock had closed below $1 for 30 consecutive business days. Trading is set to be suspended November 19 unless the company requests a hearing by November 17.
1. Delisting notice
Lakewood-Amedex Biotherapeutics said Nasdaq notified it on November 10, 2026, that its securities face delisting after its common stock closed below $1.00 for 30 consecutive business days, from September 29 through November 9. A 1-for-10 reverse stock split on June 22 makes the company ineligible for a compliance period. The company intends to request a hearing by November 17 and present a compliance plan that could include another reverse split; the request would stay suspension pending a decision.




